美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Militia Long/Short Equity ETF

38.03

+0.50001.33%

盘后：38.170.1400+0.37%16:42 EST

成交量：42.50万

成交额：1,613.08万

市值：3.48亿

市盈率：- -

高：38.24

开：37.87

低：37.68

收：37.53

52周最高：38.24

52周最低：25.85

股本：916.00万

流通股本：916.00万

量比：0.88

换手率：4.64%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

泽璟制药-U事件点评：ZG006授权给艾伯维泽速宁获批上市

甬兴证券有限公司

5000亿！一战封神，他是中国最成功的美国人

优赫得在华拓展第六个适应症，去年上半年销售额突破22亿美金

德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ORR"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.03,"timestamp":1770670800000,"preClose":37.53,"halted":0,"volume":425023,"hourTrading":{"tag":"盘后","latestPrice":38.17,"preClose":38.03,"latestTime":"16:42 EST","volume":239,"amount":9027.649965999999,"timestamp":1770673344376,"change":0.14,"changeRate":0.003681,"amplitude":0.012359},"delay":0,"changeRate":0.01332267519317879,"floatShares":9160000,"shares":9160000,"eps":0,"marketStatus":"盘后交易","change":0.5,"latestTime":"02-09 17:03:36 EST","open":37.865,"high":38.24,"low":37.675,"amount":16130842.666009998,"amplitude":0.015055,"askPrice":38.46,"askSize":100,"bidPrice":37.7,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1770685200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":37.53,"sharesOutstanding":9160000,"nav":36.92,"aum":338187200,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":37.73,"preClose":37.53,"latestTime":"08:44 EST","volume":126,"amount":4754.529864,"timestamp":1770644686174,"change":0.2,"changeRate":0.005329,"amplitude":0.000799},"postHourTrading":{"tag":"盘后","latestPrice":38.17,"preClose":38.03,"latestTime":"16:42 EST","volume":239,"amount":9027.649965999999,"timestamp":1770673344376,"change":0.14,"changeRate":0.003681,"amplitude":0.012359},"volumeRatio":0.878773,"impliedVol":0.0683,"impliedVolPercentile":0.2174},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9160000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.878773,"shares":9160000,"dividePrice":0,"high":38.24,"amplitude":0.015055,"preClose":37.53,"low":37.675,"week52Low":25.85,"pbRate":"--","week52High":38.24,"institutionHeld":0,"latestPrice":38.03,"eps":0,"divideRate":0,"volume":425023,"delay":0,"ttmEps":0,"open":37.865,"prevYearClose":34.16,"prevWeekClose":37.53,"prevMonthClose":36.48,"prevQuarterClose":34.16,"fiveDayClose":36.49,"twentyDayClose":35.38,"sixtyDayClose":32.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606259515","title":"泽璟制药-U事件点评：ZG006授权给艾伯维 泽速宁获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2606259515","media":"甬兴证券有限公司","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606259515?lang=zh_cn&edition=fundamental","pubTime":"2026-01-25 09:40","pubTimestamp":1769305230,"startTime":"0","endTime":"0","summary":"2025 年 11 月，ZG006 单药治疗晚期NEC 获 CDE 纳入突破性治疗品种公示名单，有望通过附条件批准实现早日上市。此外ZG006 联合 PD-1/PD-L1 抑制剂及化疗用于小细胞肺癌的临床试验已获批。吉卡昔替尼新入医保、泽速宁获批上市吉卡昔替尼作为首个获批国产治疗骨髓纤维化的 JAK 抑制剂成功纳入医保。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260125094033a4529cab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260125094033a4529cab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","LU1093756325.SGD","LU0545039389.USD","LU2087621335.USD","SG9999015978.USD","LU0310800379.SGD","IE00BJJMRZ35.SGD","LU0949170772.SGD","LU0689472784.USD","IE0002141913.USD","LU1496350502.SGD","LU1732800096.USD","LU1003077747.HKD","ORR","LU1023059063.AUD","LU1551013342.USD","LU1983299246.USD","BK4550","IE0009355771.USD","LU0289961442.SGD","LU0912757837.SGD","ABBV","IE00BN8TJ469.HKD","LU2112291526.USD","LU0122379950.USD","LU1037948541.HKD","LU0069063385.USD","LU2133065610.SGD","LU1496350171.SGD","IE00BFTCPJ56.SGD","LU1057294990.SGD","BK4533","LU0310799852.SGD","IE00BJT1NW94.SGD","LU2237443382.USD","LU1929549753.HKD","IE00BVYPNW00.USD","SG9999011175.SGD","LU0795875086.SGD","LU2089283258.USD","SG9999015986.USD","LU1244550577.SGD","LU1934455194.USD","LU2237443978.SGD","LU2468319806.SGD","LU0965508806.USD","LU1291159041.SGD","LU0234572021.USD","LU1989772923.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2606125812","title":"5000亿！一战封神，他是中国最成功的美国人","url":"https://stock-news.laohu8.com/highlight/detail?id=2606125812","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606125812?lang=zh_cn&edition=fundamental","pubTime":"2026-01-25 08:34","pubTimestamp":1769301264,"startTime":"0","endTime":"0","summary":"文 | 华商韬略 韩翔州2010年，旧金山的一次私人聚会上，已在中国创业有成的美国人欧雷强，结识了已在美国功成名就的中国人王晓东。终于在年底，他们决定一起冒险：在中国建立一家世界级的生物科技公司，在中国做创新药卖给全世界。作为一名连续创业者，欧雷强的履历堪称完美。事实证明，中国没有辜负欧雷强的眼光。欧雷强预见到，中国的监管环境即将迎来一场有利于创新药的剧变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769137313695679325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["PFS","BMS","LU1251922891.USD","BK1161","LU1969619763.USD","LU0588546209.SGD","BK4211","LU1719994722.HKD","BK1500","BK1588","LU1303224171.USD","BK4195","LU1770034418.SGD","LU0307460666.USD","LU2328871848.SGD","ASH","BK1583","LU2463526074.USD","06160","BK4109","ORR"],"gpt_icon":0},{"id":"2605034473","title":"优赫得在华拓展第六个适应症，去年上半年销售额突破22亿美金","url":"https://stock-news.laohu8.com/highlight/detail?id=2605034473","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605034473?lang=zh_cn&edition=fundamental","pubTime":"2026-01-23 17:13","pubTimestamp":1769159628,"startTime":"0","endTime":"0","summary":"2024 年全球已获批上市的 17 款 ADC 药物合计销售额达百亿美金，其中第一三共的德曲妥珠单抗表现尤为突出，2024 年销售额达到 34.8 亿美元、同比增长 52%。根据阿斯利康2025年上半年财报，其自身销售额为12.6亿美元，增长38%；包括合作伙伴第一三共报告的销售额在内，总销售额为22.9亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769159310955231385","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4195","OS","ORR","PFS","BK4231","BK4211","BK4080","BK4097","ADC"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠单抗胃癌新适应证获批，填补临床治疗空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605989254?lang=zh_cn&edition=fundamental","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4195","ORR","BK4080","BK4097","PFS","BK4211","ADC","OS"],"gpt_icon":0}],"pageSize":4,"totalPage":11,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}